Open Access

Effect of KRAS and NRAS mutations on the prognosis of patients with synchronous metastatic colorectal cancer presenting with liver‑only and lung‑only metastases

  • Authors:
    • Shih‑Chang Chuang
    • Ching‑Wen Huang
    • Yi‑Ting Chen
    • Cheng‑Jen Ma
    • Hsiang‑Lin Tsai
    • Tsung‑Kun Chang
    • Wei‑Chih Su
    • Wen‑Hung Hsu
    • Chao‑Hung Kuo
    • Jaw‑Yuan Wang
  • View Affiliations

  • Published online on: July 1, 2020     https://doi.org/10.3892/ol.2020.11795
  • Pages: 2119-2130
  • Copyright: © Chuang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

It has been reported that 20‑25% of patients with colorectal cancer (CRC) have metastases at the time of diagnosis. Liver and lung are the most common metastatic sites. The aim of the present study was to investigate the association of KRAS and NRAS mutations with clinicopathological features and prognosis of patients with initial liver‑metastasis only (LiM‑only) or lung‑metastasis only (LuM‑only) metastatic CRC (mCRC). Overall, 166 patients with CRC with initial LiM‑only (n=124) and LuM‑only (n=42) were retrospectively analyzed from January 2014 to December 2017. The median follow‑up time was 19.2 months (1.0‑57.1 months). Patient characteristics at diagnosis were collected. Genomic DNA was isolated from frozen primary CRC tissues for targeting KRAS and NRAS. Patients with LuM‑only were significantly older compared with those with LiM‑only (65.5 vs. 61.5 years; P=0.05). There was no significant differences between the LiM‑only and LuM‑only groups in terms of sex, location of the primary tumor, serum carcinoembryonic antigen level, histological grade and RAS mutation status. KRAS mutations were detected in 43 (41.0%) patients with LiM‑only and 13 (35.1%) patients with LuM‑only. The overall survival time (OS) of LuM‑only was more favorable compared with that of patients with LiM‑only (44.5 vs. 24.7 months); however, there was no significant difference (P=0.095). The progression‑free survival (PFS) and OS in the RAS wild‑type group were significantly improved compared with the RAS mutant cohorts (P=0.004 and P=0.031, respectively) in the LiM‑only group. In patients with stage IV CRC, those with synchronous LiM‑only mCRC had a higher incidence of metastasis but a less favorable PFS and OS compared with patients with LuM‑only. RAS mutation status exhibited a significant association with the survival outcome in patients with LiM‑only mCRC.
View Figures
View References

Related Articles

Journal Cover

September-2020
Volume 20 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Chuang SC, Huang CW, Chen YT, Ma CJ, Tsai HL, Chang TK, Su WC, Hsu WH, Kuo CH, Wang JY, Wang JY, et al: Effect of KRAS and NRAS mutations on the prognosis of patients with synchronous metastatic colorectal cancer presenting with liver‑only and lung‑only metastases. Oncol Lett 20: 2119-2130, 2020
APA
Chuang, S., Huang, C., Chen, Y., Ma, C., Tsai, H., Chang, T. ... Wang, J. (2020). Effect of KRAS and NRAS mutations on the prognosis of patients with synchronous metastatic colorectal cancer presenting with liver‑only and lung‑only metastases. Oncology Letters, 20, 2119-2130. https://doi.org/10.3892/ol.2020.11795
MLA
Chuang, S., Huang, C., Chen, Y., Ma, C., Tsai, H., Chang, T., Su, W., Hsu, W., Kuo, C., Wang, J."Effect of KRAS and NRAS mutations on the prognosis of patients with synchronous metastatic colorectal cancer presenting with liver‑only and lung‑only metastases". Oncology Letters 20.3 (2020): 2119-2130.
Chicago
Chuang, S., Huang, C., Chen, Y., Ma, C., Tsai, H., Chang, T., Su, W., Hsu, W., Kuo, C., Wang, J."Effect of KRAS and NRAS mutations on the prognosis of patients with synchronous metastatic colorectal cancer presenting with liver‑only and lung‑only metastases". Oncology Letters 20, no. 3 (2020): 2119-2130. https://doi.org/10.3892/ol.2020.11795